HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michel C Nussenzweig Selected Research

Injections

1/2019Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michel C Nussenzweig Research Topics

Disease

95Infections
01/2023 - 01/2002
39COVID-19
05/2024 - 01/2020
11Viremia
01/2021 - 10/2013
9Neoplasms (Cancer)
01/2017 - 01/2007
8Lymphoma (Lymphomas)
01/2017 - 01/2007
5Severe Acute Respiratory Syndrome
01/2024 - 12/2020
5Genetic Translocation (Chromosomal Translocation)
01/2017 - 10/2007
5Malaria
02/2016 - 12/2002
5Genomic Instability
06/2013 - 05/2002
5Ataxia Telangiectasia (Louis Bar Syndrome)
02/2013 - 11/2004
5B-Cell Lymphoma (Lymphoma, B Cell)
01/2013 - 09/2007
4Reinfection
01/2022 - 01/2020
3Breakthrough Infections
12/2022 - 10/2021
3HIV Infections (HIV Infection)
04/2022 - 01/2021
3Vesicular Stomatitis
12/2021 - 01/2021
3Pneumonia (Pneumonitis)
01/2021 - 10/2020
3Autoimmune Diseases (Autoimmune Disease)
10/2020 - 01/2004
3Inflammation (Inflammations)
04/2016 - 01/2002
3Acquired Immunodeficiency Syndrome (AIDS)
04/2015 - 06/2013
3Plasmacytoma
07/2012 - 08/2004
3Systemic Lupus Erythematosus (Libman-Sacks Disease)
07/2008 - 03/2005
2Virus Diseases (Viral Diseases)
02/2024 - 06/2023
2Burkitt Lymphoma (Burkitt's Lymphoma)
07/2012 - 08/2004
2Nijmegen Breakage Syndrome
01/2007 - 12/2001
1Convalescence
10/2021
1Kyasanur Forest Disease
01/2021
1Louping Ill
01/2021
1Asymptomatic Infections
01/2021
1Interstitial Lung Diseases (Interstitial Lung Disease)
01/2021
1Omsk Hemorrhagic Fever (Fever, Omsk Hemorrhagic)
01/2021
1Chronic Hepatitis B
12/2020
1Emerging Communicable Diseases (Emerging Infectious Diseases)
10/2020
1Zika Virus Infection
01/2020
1Microcephaly
10/2019
1Lentivirus Infections
01/2017
1Persistent Infection
01/2017
1Leukemia
01/2017
1Hepatitis A (Hepatitis, Infectious)
05/2016
1Experimental Melanoma
06/2014
1Diphtheria
02/2014

Drug/Important Bio-Agent (IBA)

66AntibodiesIBA
02/2024 - 01/2004
35Broadly Neutralizing AntibodiesIBA
01/2023 - 12/2012
26Neutralizing AntibodiesIBA
02/2024 - 09/2012
25VaccinesIBA
01/2023 - 10/2010
14Monoclonal AntibodiesIBA
05/2024 - 09/2014
13DNA (Deoxyribonucleic Acid)IBA
01/2017 - 12/2001
11AntigensIBA
08/2022 - 01/2003
10EpitopesIBA
08/2022 - 04/2009
9Cytidine DeaminaseIBA
12/2014 - 11/2009
8Immunoglobulins (Immunoglobulin)IBA
01/2020 - 08/2004
7Glycoproteins (Glycoprotein)IBA
02/2024 - 06/2004
7Proteins (Proteins, Gene)FDA Link
01/2024 - 12/2001
7Messenger RNA (mRNA)IBA
01/2023 - 01/2021
6mRNA VaccinesIBA
12/2022 - 06/2021
5AutoantibodiesIBA
01/2022 - 03/2005
5Antiviral Agents (Antivirals)IBA
04/2021 - 06/2020
5Histones (Histone)IBA
11/2008 - 12/2001
4Polysaccharides (Glycans)IBA
01/2024 - 02/2017
4chenodeoxycholate sulfate conjugate (CDCS)IBA
04/2016 - 06/2012
3Immunoglobulin G (IgG)IBA
01/2021 - 07/2008
3Antigen Receptors (Antigen Receptor)IBA
10/2007 - 01/2007
2BNT162 VaccineIBA
12/2021 - 10/2021
2remdesivirIBA
04/2021 - 01/2021
2Single-Domain AntibodiesIBA
03/2021 - 01/2021
2CytokinesIBA
01/2021 - 05/2007
2Explosive Agents (Explosives)IBA
11/2020 - 06/2020
2InterferonsIBA
10/2020 - 05/2007
2AutoantigensIBA
09/2010 - 01/2002
21,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA
11/2009 - 12/2001
2Phosphotransferases (Kinase)IBA
11/2008 - 11/2004
2Mannose ReceptorIBA
11/2003 - 01/2003
1N-(2-cyanoethylene)urea (BA 1)IBA
12/2022
1Histone Deacetylase InhibitorsIBA
11/2022
1romidepsin (FK228)FDA Link
11/2022
12019-nCoV Vaccine mRNA-1273IBA
10/2021
1ogalvibartIBA
01/2021
1Prednisolone (Predate)FDA LinkGeneric
01/2021
1crexavibartIBA
01/2021
1Immunoglobulin M (IgM)IBA
01/2021
1Immunoglobulin A (IgA)IBA
01/2021
1Biomarkers (Surrogate Marker)IBA
10/2020
1Recombinant ProteinsIBA
10/2020
1ProteomeIBA
10/2020
1Antigen-Antibody Complex (Immune Complex)IBA
01/2019
1Anti-Retroviral Agents (Antiretroviral Agents)IBA
11/2018
1Bispecific AntibodiesIBA
01/2018
1HLA-B57 antigenIBA
01/2017
1Anti-Bacterial Agents (Antibiotics)IBA
04/2016
1Indicators and Reagents (Reagents)IBA
04/2015
1LigandsIBA
06/2014
1Poly I-CIBA
06/2014
1Heparin-binding EGF-like Growth Factor (HB-EGF)IBA
02/2014
1Interleukin-23 (Interleukin 23)IBA
09/2013
1Interleukin-22 (IL-22)IBA
09/2013

Therapy/Procedure

13Therapeutics
04/2022 - 08/2009
7Immunotherapy
01/2022 - 10/2013
5Art Therapy
04/2022 - 10/2013
1Aftercare (After-Treatment)
01/2021
1Injections
01/2019
1Highly Active Antiretroviral Therapy (HAART)
11/2018